Dr. Li Hongyuan emphasized that although he agrees that in order to maintain the long-term operation of Taiwan's medical system, health insurance financial considerations are necessary. However, in terms of long-term goals, the current health insurance payment standards for incretin are not only counterintuitive in clinical practice, but also inconsistent with the current international situation. Dr. Li Hongyuan further shared that, looking at the drug payment standards of neighboring countries in Asia, there are no similar restrictions on the use of incretin in Japan, South Korea, and mainland China; there is no country in the world that requires glycosylation of hemoglobin like Taiwan.
More than 8.5%, and it can be opened for up to old picture restoration half a year. At the same time, Dr. Li Hongyuan said that according to the calculation data of the Diabetes Society and medical economics experts, if the incretin payment standard can be revised down from 8.5% of glycosylated hemoglobin to 7.5%, although the cost of medicines will increase in the short term, but in the first From three years onwards, due to the reduction of major cardiovascular and renal complications, the health insurance expenditure can be reduced by about 23 million points, which is equivalent to the sum of the increased drug expenditure in the previous two years; and about 68 million and 68 million yuan can be saved in the fourth and fifth years respectively.
At 124 million points, in the long run, the expected reduction in health care spending will be considerable. In conclusion, if the relevant units have the opportunity to relax the payment standard in the future and help people with diabetes to use incretin intervention therapy as soon as possible, it will not only help save health insurance costs, but also have the benefits of organ protection and lower mortality for people with diabetes.